High Mortality and Poor Treatment Efficacy of Immune Checkpoint Inhibitors in Severe-grade Checkpoint Inhibitor Pneumonitis in Lung Cancer

Not Applicable

Conditions: lung cancer

Registration Number: JPRN-UMIN000037184

Lead Sponsor: Japanese Red Cross Medical Center

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete: follow-up continuing

Sex: All

Target Recruitment: 71

Inclusion Criteria

Not provided

Exclusion Criteria

Patients, or family refuse to participate in this study.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality of Immune Checkpoint Inhibitors in Severe-grade Checkpoint Inhibitor Pneumonitis

Secondary Outcome Measures

Name	Time	Method
Treatment Efficacy of Immune Checkpoint Inhibitors in Severe-grade Checkpoint Inhibitor Pneumonitis

Related Trials

Treatment effect and prediction survival of Immune checkpoint inhibitors by FDG-PET/CT: A multicenter study

Not Applicable

Hyogo College of Medicine

Updated 10/17/2023

Treatment response of spirulina, omega-3 fatty acid and Vitamin E & C in OSMF

CompletedPhase 4

Maulana Azad Institute of Dental Sciences

Updated 10/17/2022

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients, affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 8/10/2021

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 9/7/2020

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 9/15/2020

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 8/10/2020

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 7/20/2020

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 1/24/2022

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 1/24/2022

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 12/10/2019

Clinical Trial Alerts

Stay informed of key developments in this trial with timely notifications for researchers and healthcare professionals.

Enrollment status and site changes

Protocol modifications and amendments

Outcome data and publication updates

Clinical Trial Alerts

Stay informed of key developments in this trial with timely notifications for researchers and healthcare professionals.

Enrollment status and site changes

Protocol modifications and amendments

Outcome data and publication updates

Home Terms & Conditions Privacy Policy